Sport video provider Whistle Sports Network has secured $28m in series B funding from Tengelmann subsidiary Emil, Liberty Global and Sky.

CoLucid Pharmaceuticals, which is working on a treatment for migraines, has secured backing from investors including Novo to take its total financing above the $100m mark.

Fosun Pharma will invest $35m in the generic pharmaceuticals producer, which will invest the cash in developing its product pipeline.

Orphazyme has secured $24m in a Novo-backed round that will fund a clinical trial for its lead drug candidate, a treatment for a rare cholesterol-caused disease.

New investors including Hearst Health Ventures and Catholic Health Initiatives have joined the company's series D round, taking its overall funding to almost $83m.

Cancer immunotherapy company Surface Oncology's $35m Eli Lilly, Amgen and Novartis-backed series A round demonstrates the recent success of oncology companies in the venture capital market.

Diabetes treatment developer Hua Medicine has completed a $25m Wuxi PharmaTech-backed round that boosted its overall funding to $75m.

GE Ventures has led a series D round for the robotics producer, increasing its total funding to $99.5m.

The online lending platform has closed its series A round at $20m, after raising $14m in a first tranche in June 2014.

Tengelmann and Access-backed online shopping club Westwing has secured $29.7m from existing investors at a $529m valuation.